{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_2",
        "name": "Zinc Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_4",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_5",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_6",
        "name": "Chelator Therapy Discontinuation",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_7",
        "name": "CRU Re-admission Window",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 1
      },
      {
        "id": "timing_8",
        "name": "Outpatient Period Extension",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_9",
        "name": "Meal Delay Post-Dose",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2
      },
      {
        "id": "timing_10",
        "name": "Outpatient Dosing Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 0,
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_11",
        "name": "Pregnancy Test Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4
      },
      {
        "id": "timing_12",
        "name": "Tetrathiomolybdate Washout",
        "type": "Before",
        "unit": "year",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "ALT/AST Elevation (High)",
        "instanceType": "Condition",
        "description": "Alanine or Aspartate aminotransferase elevation greater than 5 times the upper limit of normal.",
        "text": "ALT/AST > 5 × ULN"
      },
      {
        "id": "cond_2",
        "name": "ALT/AST Elevation (Moderate)",
        "instanceType": "Condition",
        "description": "Alanine or Aspartate aminotransferase elevation greater than 3 and less than or equal to 5 times the upper limit of normal.",
        "text": "ALT/AST > 3 × ULN and ≤ 5 × ULN"
      },
      {
        "id": "cond_3",
        "name": "Anemia",
        "instanceType": "Condition",
        "description": "Hemoglobin below 10 g/dL.",
        "text": "Hemoglobin < 10 g/dL"
      },
      {
        "id": "cond_4",
        "name": "Thrombocytopenia",
        "instanceType": "Condition",
        "description": "Platelets below 100,000/mm3.",
        "text": "Platelets < 100,000/mm3"
      },
      {
        "id": "cond_5",
        "name": "Neutropenia",
        "instanceType": "Condition",
        "description": "Neutrophils decrease more than 30% from baseline and are below the reference range.",
        "text": "> 30% ↓ from baseline Neutrophils below reference range"
      },
      {
        "id": "cond_6",
        "name": "Hy's Law Criteria",
        "instanceType": "Condition",
        "description": "Bilirubin elevation accompanied by ALT elevation, indicative of liver injury.",
        "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN"
      },
      {
        "id": "cond_7",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_8",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Evidence of clinically significant acute psychiatric worsening.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      },
      {
        "id": "cond_9",
        "name": "Pregnancy",
        "instanceType": "Condition",
        "description": "Participant becomes pregnant or is planning pregnancy.",
        "text": "Pregnancy or planned pregnancy"
      },
      {
        "id": "cond_10",
        "name": "Safety Review Committee Approval",
        "instanceType": "Condition",
        "description": "SRC must review available safety data before dose titration.",
        "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Escalation to 30mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "participants will be administered ALXN1840 at 15 mg/day for a treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29."
      },
      {
        "id": "trans_2",
        "name": "Dose Escalation Hold",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_15mg_continued",
        "text": "unless there are safety concerns that, in the opinion of the Investigator(s) and/or Alexion, may place participants at undue risk, in which case, participants may remain on the 15 mg/day dose for the duration of the study."
      },
      {
        "id": "trans_3",
        "name": "Dose Interruption for High ALT/AST",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT/AST > 5 × ULN, temporarily interrupt dosing."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Moderate ALT/AST",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT/AST > 3 × ULN and ≤ 5 × ULN, reduce dose to previous dose level or 15 mg QOD."
      },
      {
        "id": "trans_5",
        "name": "Dose Reduction for Anemia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Hemoglobin < 10 g/dL, reduce dose to previous dose level or 15 mg QOD."
      },
      {
        "id": "trans_6",
        "name": "Dose Reduction for Thrombocytopenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Platelets < 100,000/mm3, reduce dose to previous dose level or 15 mg QOD."
      },
      {
        "id": "trans_7",
        "name": "Dose Reduction for Neutropenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Neutrophils > 30% ↓ from baseline and below reference range, reduce dose to previous dose level or 15 mg QOD."
      },
      {
        "id": "trans_8",
        "name": "Dose Interruption for Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN, temporarily interrupt dosing."
      },
      {
        "id": "trans_9",
        "name": "Discontinuation for Safety",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if any of the following occur during the study: Serious hypersensitivity reaction; Severe uncontrolled infection; Use of disallowed medication; Pregnancy or planned pregnancy; or Alexion or the Investigator deems it is necessary for the participant."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discontinuation",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant... may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Escalation Decision",
        "timepointId": "pt_day29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to escalate dose from 15mg to 30mg on Day 29 is contingent on a favorable safety review by the SRC of data collected through Day 23.",
        "conditionIds": [
          "cond_10"
        ]
      },
      {
        "id": "dec_2",
        "name": "Ongoing Dose Modification Decision",
        "timepointId": "pt_ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing evaluation of safety parameters (liver function, hematology, neurologic/psychiatric status) can trigger dose modification or interruption at any time during the study.",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_8"
        ]
      },
      {
        "id": "dec_3",
        "name": "Study Intervention Discontinuation Decision",
        "timepointId": "pt_ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to discontinue a participant from the study intervention based on specific events such as pregnancy, severe infection, or hypersensitivity.",
        "conditionIds": [
          "cond_9"
        ]
      }
    ],
    "summary": {
      "timingCount": 12,
      "conditionCount": 10,
      "transitionRuleCount": 9,
      "exitCount": 4
    }
  }
}